Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
US OSHA may revoke approval of Arizona’s state OSHA plan
United States | Publication | April 2022
The Occupational Safety and Health Administration (“OSHA”) is charged with ensuring employees enjoy a safe and healthful work environment, either through the federal program or a federally-approved state plan that is at least as effective as the federal program.
The effectiveness of a state plan is virtually never an issue. Nonetheless, OSHA has announced its intent to revoke final approval of Arizona’s plan.
In particular, OSHA claims that, over the past decade, Arizona has generally failed to adopt adequate maximum penalty levels, safety and health standards, and National Emphasis Programs. More specifically, Arizona has not adopted OSHA’s COVID-19 Healthcare Emergency Temporary Standard.
View the OSHA proposal. With its April 21 publication, OSHA has started the revocation process. Public comments may be submitted by May 26. If necessary, OSHA will conduct an online evidentiary hearing on August 16.
Once OSHA considers the comments and analyzes the testimony and evidence collected in the hearing, it will publish a second notice announcing its revocation decision.
Recent publications
Publication
African nations need to present a united front at COP29 to ensure their voices are heard
Africa faces a stark reality: contributing less than 4% of global greenhouse gas emissions, the continent is disproportionately impacted by climate change, threatening its development and stability.
Publication
The GCR Guide to Life Sciences – Merger control: Procedural issues
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .